MS Trial Alert: Researchers Nationwide Recruiting Children and Adolescents with MS for a Global Study of Gilenya
Summary: Investigators across the U.S. and in other countries are recruiting 190 children and adolescents with MS (ages 10-17) for a clinical trial comparing the effectiveness of oral fingolimod (Gilenya®, Novartis Pharmaceuticals AG) with interferon beta-1a (Avonex®, Biogen Idec) injected into the muscle. The study is funded by Novartis. The U.S.
